Background
Dr. Decker, a researcher at the University of Texas MD Anderson Cancer Center, invented methods of modifying a patient’s immune system to kill cancer cells. Per his employment agreement, the patents were assigned to the University of Texas (UT) — a state entity. UT exclusively licensed the patents to Gensetix, Inc. for commercial development and required Gensetix to enforce the patents against infringers. Gensetix sued Baylor College of Medicine for infringement.
The threshold issue: Gensetix could not sue as a sole plaintiff without joining UT as a co-plaintiff, because an exclusive licensee that does not hold all substantial patent rights must join the patent owner (UT) to have standing to sue. But UT refused to join voluntarily and invoked its sovereign immunity as a state entity to resist being compelled to join the case. Without UT, could the case proceed?
The Court’s Holding
The Federal Circuit affirmed in part, holding that state sovereign immunity did indeed bar the court from compelling UT to join the lawsuit as an involuntary plaintiff. However, the court held that the district court abused its discretion by dismissing the case under Rule 19(b) (governing whether a case can proceed without a necessary party). The Federal Circuit found the case could proceed without UT because: (1) Gensetix and UT had identical interests in the patents’ validity; (2) the license agreement precluded UT from independently suing alleged infringers once Gensetix had filed suit, eliminating the risk of multiple lawsuits; and (3) dismissal would leave Gensetix without any remedy for infringement of patents it had paid to license.
The decision allowed Gensetix’s infringement case to continue even though the patent owner (UT) was not a party, using Rule 19(b) analysis to balance the competing interests.
Key Takeaways
- State universities and other sovereign entities cannot be compelled to join a patent infringement lawsuit as co-plaintiffs, even when they are the patent owner and the licensee needs their participation.
- However, courts should not automatically dismiss cases where sovereign immunity prevents joinder — they must conduct a Rule 19(b) analysis to determine if the action can proceed equitably without the absent party.
- Exclusive licensees can be permitted to proceed alone when: the patent owner has identical interests; the license agreement prevents duplicate suits; and dismissal would deny the licensee any remedy.
- University technology transfer agreements should expressly address how infringement suits will be handled if the university cannot or will not participate as a plaintiff.
Why It Matters
University patent licensing is a cornerstone of technology transfer in biotech, pharmaceuticals, and engineering. When a startup licenses cutting-edge university research, its ability to enforce those patents against competitors is essential to its commercial viability. But state universities enjoy sovereign immunity protections that can make them unwilling or unable to participate in litigation they have contractually agreed to support.
Gensetix v. Baylor clarified the rules for this common and difficult situation, giving exclusive licensees a viable path to court even when the sovereign patent owner steps back. The decision is important for any company that has licensed patents from a public university and needs to enforce them, as well as for university technology transfer offices drafting licensing agreements that need to account for the sovereign immunity problem.